Michele Davis
Registered Nurse · Mesa, AZNPI 1144395476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $421 and has fallen 93.9% since, to $26 in 2023.
Across 36 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$128
- Boehringer Ingelheim$74
- AbbVie$57
- Amarin Pharma, Inc.$52
- Abbott$49
- Lilly USA, LLC$29
- plus $197 from 13 others
What the payments were for
- Food & beverage$586100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $128 |
| Boehringer Ingelheim | 4 | $74 |
| AbbVie | 3 | $57 |
| Amarin Pharma, Inc. | 4 | $52 |
| Abbott | 3 | $49 |
| Lilly USA, LLC | 2 | $29 |
| Boston Scientific | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Amgen | 1 | $15 |
| Nevro Corp. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Medicure Pharma Inc. | 1 | $11 |
| Corium, LLC | 1 | $7 |
How this compares
$586 in reported general payments places this provider in the 85th percentile of 63 registered nurse providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $42,357 |
| JanuviaSitagliptin Phosphate | 23 | $38,480 |
| TrulicityDulaglutide | 28 | $31,812 |
| OzempicSemaglutide | 22 | $30,837 |
| MounjaroTirzepatide | 17 | $23,314 |
| JardianceEmpagliflozin | 29 | $21,961 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $12,754 |
| Repatha SureclickEvolocumab | 11 | $5,778 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,998 |
| Fentanyl | 28 | $3,926 |
| LantusInsulin Glargine,hum.Rec.Anlog | 17 | $2,932 |
| Liothyronine Sodium | 84 | $2,846 |
| Levothyroxine Sodium | 257 | $2,455 |
| Oxycodone Hcl | 72 | $2,300 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $2,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $29 | $55,12645 claims |
| PfizerEliquis | $16 | $42,35742 claims |
| Novo NordiskOzempic | $19 | $30,83722 claims |
| Boehringer IngelheimJardiance | $74 | $21,96129 claims |
| Sanofi-aventis U.S. LLCLantus | $11 | $2,93217 claims |
| AbbVieSynthroid | $57 | $1,42613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 63 registered nurse providers in Arizona.
Other registered nurse in Mesa
- Ikechi IkechiMesa$92
- Brittany LambChandler$2K
- Tanya PriceTempe$2K
- John DeangelisWinslow$1K
- Heidi PencePhoenix$1K
- Amber FessetteScottsdale$1K
- Diana NoriegaGlendale$1K
- Jenny PhillipsTucson$1K
- Maryann OphalsCave Creek$951
- Spencer JuddTucson$808
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.